Company Profile
Phathom Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Phathom Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Phathom Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Phathom Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Phathom Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
PHAT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Phathom Pharmaceuticals's catalysts are Voquezna uptake and any label-expansion or commercialization milestone. The stock moves when the acid-suppression franchise shows real commercial traction.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Source: Phathom Pharmaceuticals
- 02
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Source: Phathom Pharmaceuticals
- 03
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Source: Phathom Pharmaceuticals
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.